

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.
NHL-NP-37	10/057,311
APPLICANT	
JUNGHANS et al.	
FILING DATE	GROUP
January 24, 2002	1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
J3	AA 5 7 5 0 6 6 9	5/1998	Rösch et al.			
	AB 5 6 6 3 1 5 3	9/1997	Hutcherson et al.			
	AC 5 7 2 3 3 3 5	3/1998	Hutcherson et al.			
	AD 5 8 5 6 4 6 2	1/1999	Agrawal			
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
J3	AL 2 7 3 2 9 7 1	10/1996	France				X
	AM 9 8 2 1 3 2 2	5/1998	International	(Abstract only)		X	
	AN 0 8 5 5 1 8 4	7/1998	Europe			X	
	AO 9 8 1 8 8 1 0	5/1998	International			X	
	AP						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

J3	AQ	Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinmän DM; CpG motifs in bacterial DNA trigger direct B-cell activation; Nature 1995 Apr 6 374;6522 546-9
6	AR	Seder RA and Paul WE, Acquisition of lymphokine-producing phenotype by CD4+ T cells; Annu Rev Immunol. 1994;12:635-73
X	AS	Melief CJ, Kast WM; T-cell immunotherapy of cancer; Res Immunol 1991 Jun-Aug;142(5-6):425-9

EXAMINER *J3* DATE CONSIDERED *3/2/04*

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INITIALS *vwt*

DATE MAILED *6/13/2002*

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. NHL-NP-37	SERIAL NO. 10/057,311
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT JUNGHANS et al.	
		FILING DATE January 24, 2002	GROUP 1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AL							
AM							
AN							
AO							
AP							

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

6/83	AQ'	Pasternak G, Hochhaus A, Schultheis B, Hehlmann R; Chronic myelogenous leukemia: molecular and cellular aspects: J Cancer Res Clin Oncol 1998;124(12):643-60
✓	AR'	Weber LW, Bowne WB, Wolchok JD, Srinivasan R, Qin J, Moroi Y, Clynes R, Song P, Lewis JJ, Houghton AN; Tumor immunity and autoimmunity induced by immunization with homologous DNA; J Clin Invest 1998 Sep 15;102(6):1258-64
10	AS'	Surman DR, Irvine KR, Shulman EP, Allweis TM, Rosenberg SA, Restifo NJ; Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization; Immunol Methods; 1998 May 1;214(1-2):51-62

EXAMINER 3 DATE CONSIDERED 3/2/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.	SERIAL NO.
				NHL-NP-37	10/057,311
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT	
(Use several sheets if necessary)				JUNGHANS et al.	
				FILING DATE	GROUP
				January 24, 2002	1614

## U.S. PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
AL						YES
AM						NO
AN						
AO						
AP						

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

✓ ✓	AQ"	Kovarik J, et al. CpG Oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming; J Immunol. 1999 Feb 1;162(3):1611-7
✓	AR"	Krieg AM, Wu T, Weeratna R, Efler SM, Love-Homan L, Yang L, Yi AK, Short D, Davis HL; Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs; Proc Natl Acad Sci U S A 1998 Oct 13;95(21):12631-6
✓ ✓	AS"	Krieg AM, CpG DNA: a pathogenic factor in systemic lupus erythematosus?; J Clin Immunol 1995 Nov;15(6):284-92

EXAMINER  DATE CONSIDERED 3/2/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.	SERIAL NO.
		NHL-NP-37	10/057,311
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT	
(Use several sheets if necessary)		JUNGHANS et al.	
		FILING DATE	GROUP
		January 24, 2002	1614


## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AL							
AM							
AN							
AO							
AP							

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

  	AQ <sup>11</sup>	Sheehan and Lan, Phosphorothioate Oligonucleotides Inhibit the Intrinsic Tenase Complex, Blood 92, 1617-1625(1998)
	AR <sup>11</sup>	Lim et al., Sequence-independent inhibition of RNA transcription by DNA dumbbells and other decoys, 1997, Nuc. Acids Res. 25, 575-581; Blumenfeld et al., Nuc. Acids Res. 1993, 21, 3405-3411 → 581
	AS <sup>11</sup>	Weeratna R, Brazolot Millan CL, Krieg AM, Davis HL; Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev 1998 Aug;8(4):351-6
EXAMINER		DATE CONSIDERED 3/2/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Rev. 2-32)	U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		NHL-NP-37	10/057,311
(Use several sheets if necessary)		APPLICANT	
		JUNGHANS et al.	
		FILING DATE	GROUP
		January 24, 2002	1614

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EX 30 AQ	<p>Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Walker et al., Proc Natl Acad Sci USA 1999 Jun 8 96:12 6970-5.</p>
AR	<p>CLUSEL C ET AL.: "EX VIVO REGULATION OF SPECIFIC GENE EXPRESSION BY NANOMOLAR CONCENTRATION OF DOUBLE-STRANDED CUCKBELL OLIGONUCLEOTIDES" NUCLEIC ACIDS RESEARCH, 6B, OXFORD UNIVERSITY PRESS, SURREY, 1993.</p>
AS	<p>KRIEG A M ET AL: "OLIGOODEOXYNUCLEOTIDE MODIFICATIONS DETERMINE THE MAGNITUDE OF B CELL STIMULATION BY 'CPS MOTIFS' ANTISENSE &amp; NUCLEIC ACID DRUG DEVELOPMENT, US, MARY ANN LIEBERT, INC., NEW YORK,</p>

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INITIALS vwt

DATE MAILED 6/13/2002

FORM PTO-1M49 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. NHL-NP-37	SERIAL NO. 10/057,311
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT JUNGHANS et al.	
		FILING DATE January 24, 2002	GROUP 1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AL							
AM							
AN							
AO							
AP							

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ERJE D ET AL: "A DUMBBELL-SHAPED DOUBLE-HAIRPIN STRUCTURE OF DNA: A THERMODYNAMIC INVESTIGATION" BIOCHEMISTRY 1987, XPO02027687 the whole document.	EXAMINER AO 11111
Hosono et al, "PROPERTIES OF BASE-PAIRING IN THE STEM REGION OF HAIRPIN ANTISENSE OLIGONUCLEOTIDES CONTAINING 2'-METHOXYNUCLEOSIDES, BIOCHIM BIOPHYS, ACTA 244, 339-344 (1995)	EXAMINER AR 11111
	EXAMINER AS 11111

DATE CONSIDERED

3/2/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INITIALS vwtDATE MAILED 6/13/2002